Differential Responses of Targeted Lung Redox Enzymes to Rat Exposure to 60 or 85% Oxygen by Gan, Zhuohui et al.
Marquette University
e-Publications@Marquette
Biomedical Engineering Faculty Research and
Publications Engineering, College of
7-1-2011
Differential Responses of Targeted Lung Redox
Enzymes to Rat Exposure to 60 or 85% Oxygen
Zhuohui Gan
Marquette University
David L. Roerig
Medical College of Wisconsin
Anne V. Clough
Marquette University, anne.clough@marquette.edu
Said H. Audi
Marquette University, said.audi@marquette.edu
Accepted version. Journal of Applied Physiology, Vol. 111, No. 1 ( July 2011): 95-107. DOI. © 2011
the American Physiological Society. Used with permission.
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
1 
 
 
Differential Responses of Targeted 
Lung Redox Enzymes to Rat 
Exposure to 60 Or 85% Oxygen 
 
 
 
Zhuohui Gan 
Biomedical Engineering, Marquette University, 
Milwaukee, WI 
David L. Roerig 
Departments of Anesthesiology and Pharmacology/Toxicology, 
Medical College of Wisconsin, 
Zablocki Veterans Affairs Medical Center, 
Milwaukee, Wi 
Anne V. Clough 
Departments of Biomedical Engineering, and Mathematics, 
Statistics and Computer Science, 
Marquette University, 
Division of Pulmonary and Critical Care Medicine, 
Medical College of Wisconsin, 
Milwaukee, WI 
Said H. Audi 
Departments of Biomedical Engineering, 
Marquette University, 
Division of Pulmonary and Critical Care Medicine, 
Medical College of Wisconsin, 
Milwaukee, WI 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
2 
 
Abstract: Rat exposure to 60% O2 (hyper-60) or 85% O2 (hyper-85) for 7 
days confers susceptibility or tolerance, respectively, of the otherwise lethal 
effects of exposure to 100% O2. The objective of this study was to determine 
whether activities of the antioxidant cytosolic enzyme NAD(P)H:quinone 
oxidoreductase 1 (NQO1) and mitochondrial complex III are differentially 
altered in hyper-60 and hyper-85 lungs. Duroquinone (DQ), an NQO1 
substrate, or its hydroquinone (DQH2), a complex III substrate, was infused 
into the arterial inflow of isolated, perfused lungs, and the venous efflux rates 
of DQH2 and DQ were measured. Based on inhibitor effects and kinetic 
modeling, capacities of NQO1-mediated DQ reduction (Vmax1) and complex III-
mediated DQH2 oxidation (Vmax2) increased by ∼140 and ∼180% in hyper-85 
lungs, respectively, compared with rates in lungs of rats exposed to room air 
(normoxic). In hyper-60 lungs, Vmax1 increased by ∼80%, with no effect on 
Vmax2. Additional studies revealed that mitochondrial complex I activity in 
hyper-60 and hyper-85 lung tissue homogenates was ∼50% lower than in 
normoxic lung homogenates, whereas mitochondrial complex IV activity was 
∼90% higher in only hyper-85 lung tissue homogenates. Thus NQO1 activity 
increased in both hyper-60 and hyper-85 lungs, whereas complex III activity 
increased in hyper-85 lungs only. This increase, along with the increase in 
complex IV activity, may counter the effects the depression in complex I 
activity might have on tissue mitochondrial function and/or reactive oxygen 
species production and may be important to the tolerance of 100% O2 
observed in hyper-85 rats. 
Keywords: oxidative stress, mathematical modeling, duroquinone, 
cytochrome bc1 complex, cytochrome-c oxidase 
High o2 therapy (hyperoxia) is a necessary and effective initial 
treatment of hypoxemia or low blood Po2 in adult and pediatric 
patients with acute lung injury, such as acute respiratory distress 
syndrome.50,57 While improving O2 delivery to vital organs, sustained 
exposure to O2 at high fractions (>50%) impairs lung function.27,38,47 
Presently, the underlying mechanisms of lung O2 toxicity are not fully 
understood, and new strategies to reduce the toxic effects of this 
widely used therapy are needed.4,21 
Several animal models have been developed to evaluate the 
time course, severity, and pathophysiological mechanisms of lung O2 
toxicity.24,30,54,69 The rat model is unique in that, when adult rats are 
exposed to a sublethal 85% O2 (hyper-85) environment for 5–7 days, 
they acquire tolerance to the otherwise lethal effects of 100% O2, in 
that, if transferred to a 100% O2 environment, they survive for 
prolonged periods.6,24,33 This tolerance is not observed in other rodent 
species, but a similar tolerance occurs in humans.19,24,26,32 Conversely, 
rats exposed to 60% O2 (hyper-60) for 7 days become more 
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susceptible to 100% O2.23,40 Elucidating the factors that contribute to 
this tolerance or susceptibility of rats to 100% O2 will further 
understanding of the pathogenesis of lung O2 toxicity. In turn, this 
may suggest strategies for clinicians at the bedside to protect lung 
tissue from the toxic effects of sustained exposure to high O2.6,24,26,33 
There is ample evidence that the deleterious effects of high O2 
result from increased formation of reactive oxygen species 
(ROS).22,31,34,46 Thus previous studies have suggested a role for classic 
antioxidant enzymes (e.g., superoxide dismutases) in protection from 
O2 toxicity.24,26,42,43 Although the activities of some of these enzymes 
increase in lung homogenates from rats adapted to lethal hyperoxia, 
they do not appear to account for all aspects of this adaptive 
response.18,23,41,69 
Another proposed mechanism involved in rat tolerance of 100% 
O2 is the induction of phase II detoxification enzymes, including 
NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione-S-
transferase, and heme oxygenase-1.20,48 The induction occurs via the 
antioxidant response element, in response to oxidative or electrophilic 
stress.20,48 Phase II enzymes are, in general, involved in detoxification 
of reactive electrophilic metabolites via two-electron reduction.16,20,29 
With respect to NQO1, which is predominantly a cytosolic two-electron 
reductase,13,55 additional protective effects include regeneration of 
endogenous and exogenous antioxidants,12,29,60 scavenging 
superoxide,59,71 and competition with prooxidant one-electron quinone 
reductases (e.g., P-450 reductases) for reactive electrophilic 
metabolites and other redox active compounds.16,51,55,56,70 
Mitochondrial complexes I and III are a major source of ROS, 
and their rate of ROS production increases with O2 tension.15,66 Thus 
altering the activity of mitochondrial complex I and/or complex III 
would be an approach to control the rate of ROS production in 
response to increased O2 tension and to protect lung tissue.18 
To evaluate the activities of redox metabolic processes in a 
nondestructive manner in isolated perfused lungs, we have pursued 
the use of indicator dilution methods.5–7,9,10 These methods involve the 
bolus injection or finite-pulse infusion of indicators into the lung's 
arterial inlet, followed by measurement of concentrations of these 
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indicators in the venous effluent as a function of time. The injected 
indicators usually include an intravascular indicator plus a test 
indicator that is a substrate or ligand for the organ's metabolic 
function(s) of interest. The interactions of the test indicator with 
metabolic function(s) on passage though the organ result in 
characteristic differences between the intravascular and test indicator 
venous effluent concentration vs. time curves. The information in 
these curves about these metabolic function(s) is then deciphered 
using mathematical modeling5,9,10 
Using these indicator dilution methods and mathematical 
modeling, we have demonstrated that the redox active quinone 
compound duroquinone (DQ) is reduced to durohydroquinone (DQH2), 
and DQH2 is oxidized to DQ on passage through the pulmonary 
circulation of the isolated perfused rat lung.5,6 Based on inhibitor 
studies, NQO1 was implicated as the dominant DQ reductase and 
mitochondrial complex III as the dominant DQH2 oxidase, and the 
capacities of the lung to reduce DQ to DQH2 and oxidize DQH2 to DQ 
were shown to be measures of lung NQO1 activity and complex III 
activity, respectively.5,6 
The objective of the present study was to evaluate the effects of 
a 7-day exposure of rats to hyper-60 or hyper-85 on activities of 
NQO1 and complex III in the intact lung using DQ and DQH2, 
respectively, as indicator dilution probes. Demonstration that the 
activity of a particular redox enzyme is differentially altered by 
exposure to hyper-60 and hyper-85 would suggest a role in the 
development of the observed rat tolerance of, or susceptibility to, 
100% O2 toxicity. 
Methods 
Materials.  
DQ and other reagent grade chemicals were purchased from 
Sigma Chemical (St. Louis, MO). Bovine serum albumin (BSA; 
Standard Powder) was purchased from Serologicals (Gaithersburg, 
MD). DQH2 was prepared by reduction of DQ with potassium 
borohydride, as previously described.17 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
5 
 
Animals.  
For normoxic lung studies, male Sprague-Dawley rats (275–325 
g; Charles River) were exposed to room air. For the hyperoxic lung 
studies, age-matched rats were housed in a Plexiglas chamber 
maintained at approximately hyper-60 or hyper-85, balance N2, for 7 
days with free access to food and water.6 The total gas flow was 3.5 
l/min, and the chamber CO2 was maintained at <0.5%. The 
temperature within the chamber was maintained at 20–22°C. Every 
other day, the rats were weighed, and their cage, food, water, and CO2 
absorbent were changed. The protocol was approved by the 
Institutional Animal Care and Use Committees of the Zablocki Veterans 
Affairs Medical Center and Marquette University (Milwaukee, WI). 
Isolated, perfused lung experiments.  
As previously described, rats were anesthetized with 
pentobarbital sodium (40 mg/kg body wt ip), the trachea was 
clamped, the chest opened, and heparin (0.7 IU/g body wt) injected 
into the right ventricle. The pulmonary artery and the trachea were 
cannulated, and the pulmonary venous outflow was accessed via a 
cannula in the left atrium. The lung was removed from the chest and 
attached to a ventilation and perfusion system. The control perfusate 
contained (in mM) 4.7 KCl, 2.51 CaCl2, 1.19 MgSO4, 2.5 KH2PO4, 118 
NaCl, 25 NaHCO3, 5.5 glucose, and 5% BSA.5 The single-pass 
perfusion system was primed (Masterflex roller pump) with the control 
perfusate maintained at 37°C and equilibrated with 15% O2, 6% CO2, 
balance N2, resulting in perfusate Po2, Pco2, and pH of ∼105 Torr, 40 
Torr, and 7.4, respectively. Initially, control perfusate was pumped 
through the lung until it was evenly blanched and venous effluent was 
clear of blood. The lung was ventilated (40 breaths/min) with end-
inspiratory and end-expiratory pressures of ∼6 and 3 mmHg, 
respectively, with the above gas mixture. The pulmonary arterial 
pressure was referenced to atmospheric pressure at the level of the 
left atrium and monitored continuously during the course of the 
experiments. The venous effluent pressure was atmospheric pressure. 
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Pulse infusion experimental protocols.  
To determine the DQ reducing capacity of the lung, four 135-s 
sequential arterial pulse infusions at DQ concentrations of 50, 100, 
200, and 400 μM were carried out with a perfusate flow of 10 ml/min. 
For each pulse infusion, a venous effluent sample (1 ml) was collected 
between 130 and 135 s after initiation of the pulse infusion. Infusion 
for 130 s is long enough for the venous effluent concentrations of DQ 
and DQH2 to reach steady state.5,6 Between pulse infusions, the lung 
was perfused with 30 ml of fresh perfusate to wash the lung and 
perfusion system of any remaining traces of DQ and/or DQH2. For 
some of the lungs, the 400 μM DQ pulse infusion was repeated after 
lung treatment with the NQO1 inhibitor dicumarol (400 μM). 
To determine the capacity of NQO1-mediated DQ reduction on 
passage through the pulmonary circulation, each lung was perfused for 
5 min with perfusate containing antimycin A (10 μM) to inhibit complex 
III mediated DQH2 oxidation.14 This was followed by four successive 
DQ pulse infusions, as above, with the inhibitor present throughout the 
infusion protocol. 
To evaluate the capacity of complex III-mediated DQH2 
oxidation on passage through the pulmonary circulation, each lung 
was perfused for 5 min with perfusate containing dicumarol (NQO1 
inhibitor; 400 μM) or dicumarol plus rotenone (complex I inhibitor; 20 
μM).5,6,9 This was followed by four 135-s sequential arterial pulse 
infusions at DQH2 concentrations of 50, 100, 200, and 400 μM at a 
flow of 10 ml/min, with the inhibitors present throughout the infusion 
protocol. A 1-ml venous effluent sample was collected between 130 
and 135 s after initiation of each pulse infusion. For some of the lungs, 
the 400 μM DQH2 infusion was repeated after lung perfusion with 
antimycin A. 
For determination of perfused lung surface area, a 150 μM 20-s 
pulse infusion of the angiotensin converting enzyme (ACE) substrate 
N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly (FAPGG) was carried out at a 
perfusate flow of 30 ml/min.6 Two 1-ml venous effluent samples were 
collected between 15 and 20 s after the start of the FAPGG infusion.6 
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Determination of DQ and DQH2 concentrations in 
venous effluent samples.  
The concentrations of DQ and DQH2 in the venous effluent 
samples were determined as previously described.5 At steady state, 92 
± 3% (SD) and 95 ± 4% (SD) of the infused DQ and DQH2, 
respectively, were recovered in the total venous effluent as DQ + 
DQH2, with the loss attributable primarily to binding of both forms to 
the experimental tubing (data not shown). 
Steady-state DQH2 or DQ efflux rates.  
The steady-state efflux rates of DQH2 or DQ from the lung 
during DQ or DQH2 arterial infusion were calculated as the product of 
the perfusate flow (10 ml/min) and the steady-state venous effluent 
DQH2 or DQ concentrations, respectively. 
Log mean DQ and DQH2 concentrations.  
DQ vascular concentration during DQ arterial infusion decreases 
as it passes through the capillary region due to reduction. Thus the 
effective DQ concentration in the capillary region during DQ arterial 
infusion is given by its log mean,  
Log mean DQ conc. =
[DQ̅̅ ̅̅ ]in − [DQ̅̅ ̅̅ ]out
ln([DQ̅̅ ̅̅ ]in/[DQ̅̅ ̅̅ ]out)
 
(1) 
where [DQ̅̅ ̅̅ ]in and [DQ̅̅ ̅̅ ]out are the arterial infused and venous effluent 
steady-state DQ concentrations, respectively5 Similarly, the effective 
DQH2 concentration in the capillary region during DQH2 arterial 
infusion is given by,  
Log mean DQH2 conc. =
[DQH̅̅ ̅̅ ̅̅ 2]in − [DQH̅̅ ̅̅ ̅̅ 2]out
ln([DQH̅̅ ̅̅ ̅̅ 2]in/[DQH̅̅ ̅̅ ̅̅ 2]out)
  
(2) 
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where [DQH̅̅ ̅̅ ̅̅ 2]in and [DQH̅̅ ̅̅ ̅̅ 2]out are the arterial infused and venous 
effluent steady-state DQH2 concentrations, respectively. 
Determination of perfused capillary surface area.  
The linear steady-state rate of ACE-mediated FAPGG hydrolysis is 
represented as a permeability-surface area product (PS, ml/min) 
defined by Eq. 3 :6  
PS=−F ln(1−E) 
(3) 
where E = steady-state extraction ratio = 1 − [FAPGG]o/[FAPGG]i; 
[FAPGG]i is the infused arterial FAPGG concentration; [FAPGG]o is the 
steady-state venous effluent FAPGG concentration calculated as the 
average [FAPGG] in the collected venous effluent samples; and F is the 
perfusate flow.6 In the present study, the PS product is considered to 
be an index of perfused capillary endothelial surface area.5,6,9 
Lung homogenate NQO1 activity.  
For this assay, the lungs were perfused with perfusate 
containing 2.5% Ficoll instead of 5% BSA, weighed, and placed in ice-
cold buffer (5 ml/g lung tissue, pH 7.4) containing (in mM) 10 N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 250 
sucrose, 3 EDTA, 1 phenylmethylsulfonyl fluoride, and 1% protease 
inhibitor cocktail (Sigma catalog no. P8340). The lungs were first 
minced and then homogenized at 4°C using a Polytron tissue 
homogenizer (Kinematica, Luzern, Switzerland). The lung homogenate 
was centrifuged (12,100 g) at 4°C for 30 min, and the supernatant 
was collected and kept at 4°C. The supernatant protein concentration 
and NQO1 activity were measured as previously described.6 
Complexes I and IV assays.  
The lungs were perfused with perfusate containing 2.5% Ficoll 
instead of 5% BSA, weighed, minced, and homogenized as above with 
buffer (pH 7.2) containing (in mM) 225 mannitol, 75 sucrose, 5 3-(N-
morpholino)propanesulfonic acid, 20 ethylene glycol-bis(β-aminoethyl 
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ether)-N,N,N′,N′-tetraacetic acid, 2% fatty-acid free BSA, and 0.02 
ml/ml protease inhibitor cocktail set III (Calbiochem, La Jolla, CA), 
utilizing a Polytron tissue homogenizer. Lung homogenates were 
centrifuged at 1,500 g for 5 min at 4°C, and the resulting supernatants 
were centrifuged again at 13,000 g for 30 min at 4°C to obtain a crude 
mitochondrial fraction (P2). The P2 fractions were washed twice by 
resuspension in 8 ml ice-cold homogenization buffer without BSA and 
then centrifuged (13,000 g for 20 min at 4°C). The final P2 fractions 
were resuspended in 1-ml BSA-free homogenization buffer. Complex I 
activity was measured using the method of Lenaz et al.,44 as 
previously described.9 Mitochondrial complex IV activity was measured 
as described by Storrie and Madden61 using ferrocytochrome c as the 
substrate. The protein concentrations were determined as previously 
described.6,9 
Total glutathione content.  
For this assay, the lungs were perfused with buffer containing 
(in mM) 10 HEPES, 5 glucose, and 5% dextran (∼67,000 mol wt), pH 
7.4. The lungs were then dissected free from connective tissue and 
weighed. The tissue was then placed into 10 volumes (per lung wet 
weight) of 4°C sulfosalicylic acid (5%), minced, and homogenized as 
above. The homogenate was centrifuged (10,000 g) at 4°C for 20 min, 
and the supernatant was used to determine total lung glutathione 
content, as described by Owens and Belcher49 and modified by Tietze65 
and Griffith.39 
Statistical evaluation of data.  
Statistical comparisons were carried out using t-test or ANOVA 
followed by Tukey's test, with P < 0.05 as the criterion for statistical 
significance. 
Results 
Rats lost ∼14% of their preexposure body weights (Fig. 1) over 
the 7-day hyper-85 exposure period, consistent with results from 
previous studies.24,52 Most of this weight loss occurred between days 2 
and 6, during which the rats' water and food intake decreased 
substantially. On the other hand, rats exposed to hyper-60 gained 
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body weight steadily over the 7-day exposure period at a rate that is 
virtually the same as that of age-matched normoxic rats.23 Subsequent 
determination of model parameters is unaffected by the body weight 
loss of hyper-85 rats, since normalization is done with respect to dry 
lung weight rather than body weight. 
 
Fig. 1. Rat body weights normalized to preexposure body weights at different time 
points during the 7-day exposure period to room air (normoxic), 60% O2 (hyper-60), 
or 85% O2 (hyper-85). Values are means ± SE (n = 6, 33, and 34 for normoxic, 
hyper-60, and hyper-85 rats, respectively). Normalized weights at a given time are 
significantly different from normalized weights at the previous time point for 
*normoxic, # hyper-60, or & hyper-85 rats, respectively (P < 0.05). 
Rat exposure to hyper-85 for 7 days (hyper-85) increased lung 
wet weight by 87%, with no significant effect on wet-to-dry weight 
ratio compared with normoxic lungs (Table 1). The lack of a significant 
difference in wet-to-dry weight ratios between normoxic and hyper-85 
lungs (Table 1) is consistent with the finding of Crapo et al.24 that the 
increase in wet weight was due to increased tissue mass not edema. 
Hyper-60 lung wet weights and wet-to-dry weight ratios were not 
different from normoxic lungs (Table 1).40 
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Table 1. Rat body weights, lung weights, lung wet-to-dry weight ratio, ACE 
activity, and aortic blood Hct 
 Body Weight, g Wet Weight, g Wet-to-Dry Ratio PS, ml/min Hct, % 
Normoxic 316 ± 4 1.22 ± 0.03 5.56 ± 0.09 24.7 ± 1.7 43.5 ± 0.4 
Hyper-60 302 ± 2* 1.31 ± 0.02 5.45 ± 0.05 25.1 ± 1.4 33.5 ± 0.6* 
Hyper-85 311 ± 2 2.29 ± 0.08*† 5.72 ± 0.08 10.7 ± 0.8*† 50.1 ± 0.8*† 
Values are means ± SE; n values are as follows for body weight, lung wet weight, wet-
to-dry ratio, permeability surface area product (PS), and hematocrit (Hct), 
respectively: normoxic lungs, n = 38, 38, 31, 19, and 27 (38 is the total number of 
normoxic rats studied); hyper-60 (60% O2 exposure) lungs, n = 38, 38, 29, 18, and 
23 (38 is the total number of hyper-60 rats studied); hyper-85 (85% O2 exposure) 
lungs, n = 41, 41, 28, 20, and 27 (41 is the total number of hyper-85 rats studied). 
Body weight is the value at the beginning of the 7-day exposure period. PS is measure 
of angiotensin-converting enzyme (ACE) mediated N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly 
hydrolysis and an index of perfused capillary surface area. Significantly different from 
* normoxic and †hyper-60 values, P < 0.05. 
Exposure to hyper-85 for 7 days decreased PS (ml/min), an 
index of perfused capillary endothelial surface area, by 56% compared 
with normoxic lungs (Table 1). This is consistent with the 50% 
decrease in capillary volume and endothelial surface area measured 
morphometrically.24,25,52 The PS values for hyper-60 and normoxic 
lungs were not significantly different. This is consistent with no change 
in morphometric measures of capillary volume and endothelial surface 
area between normoxic and hyper-60 lungs.40 
Rat exposure to hyper-85 and hyper-60 had a differential effect 
on aortic blood hematocrit (Table 1). Exposure to hyper-85 increased 
hematocrit by 16%, while exposure to hyper-60 decreased it by 12% 
compared with normoxic lungs.24 The increase in aortic blood 
hematocrit of hyper-85 rats is consistent with that reported in previous 
studies.24,25 Those studies suggested that this decrease could be due 
to dehydration, consistent with the measured body weight loss in 
hyper-85 rats (Table 1). There was no significant difference in the 
isolated lung perfusion pressure at 10 ml/min among the three groups 
of lungs.52 
For hyper-60 and hyper-85 lungs, the DQH2 efflux rates during 
the arterial infusion of DQ at the two highest concentrations were, on 
average, 37% higher than in normoxic lungs (Fig. 2). For all three lung 
groups, lung treatment with dicumarol (NQO1 inhibitor) decreased the 
rate of DQH2 efflux by >95% during the infusion of DQ at the highest 
concentration. This is consistent with NQO1 being the dominant 
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reductase of DQ on passage through the pulmonary circulation of 
normoxic, hyper-60, and hyper-85 lungs.5,6 
 
Fig. 2. The relationship between the steady-state rate of durohydroquinone (DQH2) 
efflux and the log mean duroquinone (DQ) concentrations, which are effective 
intravascular DQ concentrations during DQ arterial infusion, for normoxic lungs (n = 
4), hyper-85 lungs (n = 5), and hyper-60 lungs (n = 5). Values are means ± SE. The 
solid lines are model fits to the mean values of the data. *Hyper-60 rates significantly 
different from the normoxic rates at the same log mean DQ concentrations; # hyper-
85 rates significantly different from the normoxic rates at the same log mean DQ 
concentrations (P < 0.05). 
To evaluate the capacity of the lung to oxidize DQH2, we 
measured the steady-state rate of DQ efflux during DQH2 infusion in 
the presence of dicumarol to inhibit DQ reduction (Fig. 3). For hyper-
60 and hyper-85 lungs, the rates of DQ efflux during DQH2 infusion at 
the two highest concentrations were 40% higher than in normoxic 
lungs (Fig. 3). For all three groups of lungs, treatment with antimycin 
A (complex III inhibitor) decreased the rate of DQ efflux to nearly zero 
during DQH2 infusion at the highest concentration. This is consistent 
with DQH2 oxidation on passage through normoxic and hyperoxic lungs 
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occurring predominately via the hydroquinone oxidase-cytochrome c 
reductase activity of complex III.5,6 
 
Fig. 3. The relationship between the steady-state rate of DQ efflux and the log mean 
DQH2 concentrations, which are the effective intravascular DQH2 concentrations during 
DQH2 arterial infusion in the presence of dicumarol (DIC, 400 μM), for normoxic lungs 
(n = 6), hyper-85 lungs (n = 6), and hyper-60 lungs (n = 4). Values are means ± SE. 
The solid lines are model fits to the mean values of the data. *Hyper-60 rates 
significantly different from the normoxic rates at the same log mean DQH2 
concentrations; # hyper-85 rates significantly different from the normoxic rates at the 
log mean DQH2 concentrations (P < 0.05). 
To evaluate the effect of rat exposure to hyper-60 or hyper-85 
on NQO1-mediated DQ reduction, the rate of DQH2 efflux during DQ 
infusion was measured in the presence of antimycin A to inhibit DQH2 
oxidation (Fig. 4). As expected, antimycin A increased the rates of 
DQH2 efflux (Figs. 2 and and 4) over the range of infused DQ 
concentrations. Moreover, both O2 levels increased the rate of DQH2 
efflux during DQ infusion at the two highest concentrations in the 
presence of antimycin A compared with normoxic lungs, but the 
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increase was larger for the hyper-85 lungs (52%) than for the hyper-
60 lungs (23%) (Fig. 4). 
 
Fig. 4. The relationship between the steady-state rate of DQH2 efflux and the log 
mean DQ concentrations, which are the effective intravascular DQ concentrations 
during DQ arterial infusion in the presence of antimycin A (AA, 10 μM), for normoxic 
lungs (n = 5), hyper-85 lungs (n = 5), and hyper-60 lungs (n = 5). Values are means 
± SE. The solid lines are model fits to the mean values of the data. *Hyper-60 rates 
significantly different from the normoxic rates at the same log mean DQ 
concentrations; # hyper-85 rates significantly different from the normoxic rates at the 
same log mean DQ concentrations (P < 0.05). 
To evaluate the effect of rat exposure to hyper-85 or hyper-60 
on mitochondrial complex III-mediated DQH2 oxidation, the rate of DQ 
efflux during DQH2 infusion was measured in the presence of 
dicumarol and rotenone. Again, rotenone was added to minimize 
competition between DQH2 and reduced endogenous coenzyme Q9 
hydroquinone (CoQ9H2) for oxidation via complex III. Figure 5 shows 
that, for hyper-85 lungs, the steady-state rates of DQ efflux during 
DQH2 infusion at the two highest concentrations in the presence of 
dicumarol plus rotenone were ∼30% higher than those in normoxic 
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lungs. For all three groups of lungs, the rate of DQ efflux during DQH2 
infusion at the highest concentration in the presence of antimycin A 
along with dicumarol and rotenone was virtually zero. This further 
supports that complex III is the dominant site for DQH2 oxidation on 
passage through the pulmonary circulation of all three groups of lungs. 
 
Fig. 5. The relationship between the steady-state rate of DQ efflux and the log mean 
DQH2 concentrations, which are the effective intravascular DQH2 concentrations during 
DQH2 arterial infusion in the presence of DIC (400 μM) plus rotenone (ROT, 20 μM), 
for normoxic lungs (n = 4), hyper-85 lungs (n = 4), and hyper-60 lungs (n = 4). 
Values are means ± SE. The solid lines are model fits to the mean values of the data. 
& Hyper-85 rates significantly different from the normoxic rates at the same log mean 
DQH2 concentrations (P < 0.05). 
Table 2 shows that rat exposure to hyper-85 increased NOQ1 
homogenate activity per lung by 72%, but had no significant effect on 
NQO1 activity per milligram of protein. Exposure to hyper-60, on the 
other hand, had no significant effect on NQO1 activity in homogenate 
per lung or per milligram of protein. 
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Table 2. Lung homogenate NQO1 activity 
 Homogenate NQO1 Activity 
 
 μmol · min−1 · lung−1 nmol · min−1 · mg protein−1 
Normoxic 26.48 ± 1.67 670 ± 80 
Hyper-60 34.75 ± 1.98 737 ± 63 
Hyper-85 45.55 ± 4.74*† 538 ± 43 
Values are means ± SE; n = 7, 10, and 7 for normoxic, hyper-60, and hyper-85 lungs, 
respectively. NQO1, NAD(P)H:quinone oxidoreductase 1. Significantly different from 
the corresponding * normoxic and † hyper-60 values, P < 0.05. 
We also measured the activities of mitochondrial complexes I 
and IV in lung tissue homogenates. Table 3 shows that mitochondrial 
complex I activities per milligram protein were ∼50% lower in P2 
fractions derived from hyper-85 and hyper-60 lungs than normoxic 
lungs. Complex IV activity per milligram protein increased in only 
hyper-85 lung homogenates by 90% compared with normoxic lungs 
(Table 3). 
Table 3. Mitochondrial complexes I and IV activities measured in P2 fractions 
of lung homogenates 
 Complex I Activity Complex IV Activity 
Normoxic 13.18 ± 2.31 231.8 ± 15.9 
Hyper-60 6.49 ± 0.84* 201.8 ± 45.8 
Hyper-85 6.78 ± 1.24* 439.3 ± 50.8* 
Values are means ± SE in nmol · min−1 · mg protein−1; for complexes I and IV 
activities, n = 5, 5, and 7 for normoxic, hyper-60, and hyper-85 lungs, respectively. 
*Significantly different from the corresponding normoxic value, P < 0.05. 
 
Table 4 shows that total glutathione content (oxidized plus 
reduced glutathione) per lung and per gram of dry lung weight 
increased by 101 and 20%, respectively, in hyper-85 lungs only 
compared with normoxic lungs. 
Table 4. Total lung glutathione (GSH + GSSG) content 
 (GSH + GSSG), μmol/lung (GSH + GSSG), μmol/g dry wt 
Normoxic 2.34 ± 0.17 10.23 ± 0.55 
Hyper-60 3.09 ± 0.14 11.96 ± 0.77 
Hyper-85 4.70 ± 0.39*† 12.21 ± 0.47* 
Values are means ± SE; n = 8, 5, and 7 for normoxic, hyper-60, and hyper-85 lungs, 
respectively. GSH, reduced glutathione; GSSG oxidized glutathione. Significantly 
different from the corresponding * normoxic and † hyper-60 values, P < 0.05. 
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Data analysis.  
The data in Figs. 22–5 are the net result of multiple factors, 
including 1) DQ and DQH2 interactions with competing nonlinear tissue 
redox processes; 2) DQ and DQH2 interactions with protein (i.e., BSA) 
in the vascular space; and 3) capillary perfusion kinematics [i.e., a 
heterogeneous distribution, hc(t), of capillary transit times]. Thus, for 
quantitative interpretation of the data in Figs. 22–5, we utilized a 
whole lung kinetic model consisting of a capillary region that accounts 
for DQ and DQH2 tissue and vascular interactions and conducting 
arteries and veins.52 The capillary region has a hc(t).5,6,9 The model 
was used to estimate parameters descriptive of the activities of NQO1 
and complex III in the isolated perfused lung from the data in Figs. 22
–5. 
The capillary region is modeled as parallel noninteracting 
capillary elements with transit times distributed according to hc(t).8 
Figure 6 shows a single capillary element consisting of a vascular 
region and its surrounding lung tissue region with volumes Vc (ml) and 
Ve (ml), respectively. Within the vascular region, DQ and DQH2 
participate in nonspecific and rapidly equilibrating interactions with the 
perfusate albumin (BSA). The free (i.e., not BSA bound) vascular 
concentrations of DQ and DQH2 can freely permeate the tissue region 
from the vascular region. Within the tissue region, DQ is reduced via 
NQO1, and DQH2 is oxidized via mitochondrial complex III. This 
reduction and oxidation are assumed to follow Michaelis-Menten 
kinetics, where Vmax and Km represent the maximum reduction or 
oxidation rate and Michaelis-Menten constant, respectively. All 
nonspecific DQ and DQH2 interactions are assumed to follow the law of 
mass action. The above assumptions were incorporated into a 
differential equation model presented in the appendix. 
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Fig. 6. A schematic representation of the vascular and lung tissue interactions of DQ 
and DQH2 in a single capillary element consisting of a vascular region and its 
surrounding tissue region. Within the vascular region, DQ and DQH2 participate in 
nonspecific and rapidly equilibrating interactions with the perfusate BSA, Pc. Within the 
tissue region, DQ is reduced via NAD(P)H:quinone oxidoreductase 1 (NQO1), and 
DQH2 is oxidized via complex III. Also within the tissue volume, DQ and DQH2 undergo 
nonspecific rapidly equilibrating interactions with lung tissue, Pe. CytoC (oxid.) and 
cytoC (red.) are the oxidized and reduced forms of cytochrome c, respectively. 
Estimation of model parameters.  
The unknown model parameters under steady-state conditions 
(see appendix) are Vmax1 (μmol/min) and Vmax2 (μmol/min), the 
respective maximum rates for DQ reduction via NQO1 and DQH2 
oxidation via complex III; Km1a (μM) and Km2a (μM), the apparent 
Michaelis-Menten constants for NQO1-mediated DQ reduction and 
complex III-mediated DQH2 oxidation, respectively; and kox (ml/min), 
the tissue-mediated DQH2 oxidation rate on passage through the 
pulmonary circulation in the absence of rotenone. 
The values of these parameters for each of the three groups of 
lungs were estimated using the following approach. First, the values of 
Vmax1 and Km1a, parameters descriptive of NQO1-mediated DQ 
reduction, were determined. This was done by fitting the steady-state 
solution of the lung model to the steady-state rates of DQH2 efflux 
during DQ infusion in the presence of antimycin A (Fig. 4), which 
corresponded to setting Vmax2 to zero in Eqs. A1 and A2. The estimated 
values of these model parameters are given in Table 5. Rat exposure 
to hyper-85 for 7 days increased Vmax1 by ∼200%. The estimated 
values of Vmax1 for hyper-60 lungs tended to be higher than those for 
normoxic lungs, but the mean difference was not significant (one-way 
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ANOVA). For all three groups of lungs, the estimated value of Km1a was 
1 μM, which was the lower bound set for this parameter in the least 
squares fitting procedure. Km1a is an intensive property of the enzyme 
and hence would be expected to be the same for all three groups of 
lungs. 
Table 5. Values of model parameters descriptive of NQO1-mediated DQ 
reduction in normoxic and hyperoxic lungs estimated from the steady-state 
DQH2 efflux rates during DQ infusion in the presence of antimycin A 
 Vmax1 
 
 
 μmol/min μmol · min−1 · g dry wt−1 Kma1, μM 
Normoxic 1.38 ± 0.07 6.4 ± 0.3 1.0 
Hyper-60 1.84 ± 0.06 7.8 ± 0.5 1.0 
Hyper-85 4.11 ± 0.39*† 10.8 ± 0.7*† 1.0 
Values are means ± SE; n = 5 for all three groups. Vmax1, maximum duroquinone (DQ) 
reduction rate; Kma1, apparent Michaelis-Menten constant. DQH2, durohydroquinone. 
Significantly different from * normoxic and † hyper-60 values, P < 0.05. 
For a given lung, parameters descriptive of complex III-
mediated DQH2 oxidation (Vmax2 and Km2a) were estimated by fitting 
the steady-state solution of the organ model to the rates of DQ efflux 
during DQH2 infusion in the presence of dicumarol and rotenone (Fig. 
5), with Vmax1 set to zero in Eqs. A1 and A2 to account for the presence 
of dicumarol. Results in Table 6 show that exposure to hyper-85 
increased Vmax2 by ∼180%, compared with normoxic lungs, with no 
significant effect on Km2a. The estimated values of Vmax2 and Km2a for 
hyper-60 lungs were not significantly different from those estimated 
for normoxic lungs. 
Table 6. Values of model parameters descriptive of complex III-mediated 
DQH2 oxidation in normoxic and hyperoxic lungs estimated from the steady-
state DQ efflux rates during DQH2 infusion in the presence of dicumarol plus 
rotenone 
 Vmax2 
 
 
 μmol/min μmol · min−1 · g dry wt−1 Kma2, μM 
Normoxic 1.67 ± 0.10 8.7 ± 0.7 42 ± 2 
Hyper-60 2.07 ± 0.09 8.8 ± 0.5 38 ± 6 
Hyper-85 4.65 ± 0.36*† 13.6 ± 1.8*† 36 ± 11 
Values are means ± SE. n = 4 for all three groups. Vmax2, maximum DQH2 oxidation 
rate; Kma2, apparent Michaelis-Menten constant. Significantly different from * 
normoxic and † hyper-60 values, P < 0.05. 
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In the absence of rotenone (complex I inhibitor), DQH2 
competes with CoQ9H2 for oxidation via complex III. This competition 
explains the observation that the rates of DQ efflux during DQH2 
infusion in the presence of dicumarol alone are lower than those in the 
presence of dicumarol plus rotenone (Figs. 3 and and 5). Moreover, 
the steady-state DQ efflux rates during DQH2 infusion in the presence 
of dicumarol alone appear to follow linear kinetics for the range of 
infused DQH2 concentrations studied (Fig. 3). Thus, in the absence of 
rotenone, Vmax2 and Km2a in Eqs. A1 and A2 (appendix) are substituted 
for with kox (Eqs. A3 and A4). To put kox in perspective, if one were to 
assume Michaelis-Menten kinetics for DQH2 oxidation in the presence 
of dicumarol alone, kox would be the ratio of the maximum oxidation 
rate over the Michaelis-Menten constant. 
The value of kox was estimated by fitting the model, with Vmax1 
set to zero in Eqs. A3 and A4, to the steady-state rates of DQH2 efflux 
during DQ infusion in the presence of dicumarol (Fig. 3). Table 7 
shows that rat exposure to hyper-60 or hyper-85 for 7 days increased 
the estimated value of kox by ∼70 and ∼140%, respectively, compared 
with normoxic lungs. 
Table 7. Value of model parameter descriptive of the DQH2 oxidation capacity 
in normoxic and hyperoxic lungs estimated from the steady-state DQ efflux 
rates during DQH2 infusion in the presence of dicumarol 
 kox 
 
 ml/min ml · min−1 · g dry wt−1 
Normoxic 6.38 ± 0.60 27.6 ± 2.9 
Hyper-60 10.84 ± 1.25* 43.1 ± 4.0*‡ 
Hyper-85 15.16 ± 1.58*† 35.0 ± 8.4 
Values are means ± SE; n = 6, 4, and 6 for normoxic, hyper-60, and hyper-85 lungs, 
respectively. kox, rate of DQH2 oxidation on passage through the pulmonary 
circulation. Significantly different from * normoxic, † hyper-60, and ‡ hyper-85 
values, P < 0.05. 
A second estimate of the values of Vmax1 and Km1a for normoxic 
and hyperoxic lungs was obtained by fitting the steady-state organ 
model solution to the steady-state rates of DOH2 efflux during DQ 
infusion in the absence of inhibitors (Fig. 2), with kox in Eqs. A3 and A4 
set to the mean values in Table 7. The estimated values of Vmax1 for 
hyper-60 and hyper-85 lungs were ∼80 and 140% higher than that 
estimated for normoxic lungs, respectively (Table 8). 
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Table 8. Values of model parameters descriptive of NQO1-mediated DQ 
reduction in normoxic and hyperoxic lungs estimated from the steady-state 
DQH2 efflux rates during DQ infusion 
 Vmax1 
 
 
 μmol/min μmol · min−1 · g dry wt−1 Kma1, μM 
Normoxic 1.46 ± 0.10 7.2 ± 0.8 4.4 ± 1.4 
Hyper-60 2.64 ± 0.08* 11.8 ± 0.5* 12.5 ± 2.1*‡ 
Hyper-85 3.52 ± 0.12*† 10.1 ± 0.6* 6.4 ± 1.6 
Values are means ± SE; n = 4, 5, and 5 for normoxic, hyper-60, and hyper-85 lungs, 
respectively. kox was set to the mean value in Table 5. Significantly different from * 
normoxic, † hyper-60, and ‡ hyper-85 values, P < 0.05. 
For normoxic and hyper-85 lungs, the values of Vmax1 in Table 8 
vs. Table 5, i.e., estimated from the steady-state rates of DQH2 efflux 
during DQ infusion in the absence or presence, respectively, of 
antimycin A were not significantly different. This is consistent with the 
hypothesis that the dominant effect of antimycin A is on complex III-
mediated DQH2 oxidation. However, for hyper-60 lungs, the estimated 
values of Vmax1 were statistically different for the two approaches. 
Discussion 
The results of the present study demonstrate that rat exposure 
to hyper-85 vs. hyper-60 differentially altered the lung tissue complex 
III and IV activities, and GSH content, but had similar effects on NQO1 
and complex I activities. In hyper-85 rats, the capacity of Vmax1 and 
Vmax2 increased by 140 and 180%, respectively, on passage through 
the pulmonary circulation. However, hyper-60 increased Vmax1 by 80%, 
with no effect on Vmax2. Additional results demonstrate that hyper-60 
and hyper-85 decreased complex I activity by ∼50%, and that hyper-
85, but not hyper-60, increased complex IV activity and GSH tissue 
content by 90 and 20%, respectively. 
In addition to increasing Vmax1 and Vmax2, rat exposure to hyper-
85 increased lung dry weight (Table 1), presumably due to a large 
increase in the number of interstitial cells.24,25 This brought into 
question whether the estimated increase in these extensive kinetic 
parameters was simply the result of an increase in tissue mass (i.e., 
more cells). As shown in Tables 6 and and 8, the increase in the dry 
weight of hyper-85 lungs cannot account for all of the increase in the 
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values of Vmax1 and Vmax2, since the values per gram of dry lung are, 
respectively, 40 and 56% higher than corresponding values for 
normoxic lungs. The above results suggest that rat exposure to hyper-
85 induced an increase of 40 and 56% in the lung activities of NQO1 
and complex III per gram of dry lung weight, respectively. 
For normoxic and hyper-85 lungs, the estimates of Vmax1 
obtained using two independent data sets, i.e., DQH2 efflux rates 
during DQ infusion in the absence or presence of antimycin A, are not 
significantly different (Tables 5 and and 8). However, for hyper-60 
lungs, the difference in these values is 42%. One reason for this 
difference might be that treatment of hyper-60 lungs with antimycin A 
not only inhibited complex III-mediated DQH2 oxidation, but also 
partially inhibited NQO1-mediated DQ reduction or other DQ 
reductase(s).68 In addition to inhibiting DQH2 oxidation, antimycin A 
would be expected to inhibit ATP production via oxidative 
phosphorylation. This impairment to ATP production could stimulate 
glycolysis1–3, 58 This, in turn, would divert glucose-6-phosphate from 
the pentose phosphate pathway, the main source of NADPH for 
NOQ1.13 This suggests that, for hyper-60 lungs, the rate of NAPDH 
production in the presence of antimycin A may not be sufficient to 
maintain the maximum capacity of NQO1 for DQ reduction that is 
measurable in the absence of antimycin A (Figs. 2 and and4). This 
explanation is consistent with previous studies that demonstrated that 
rat exposure to hyper-85, but not hyper-60, increased lung activities 
of glucose transporters, hexokinase, and glucose-6-phosphate 
dehydrogenase (G-6-PHD) compared with normoxic lungs (Table 9).1–
3,40,64 
Table 9. Summary of the effect of rat exposure to hyper-60 or hyper-85 for 7 
days on cell surface, cytosolic, and mitochondrial enzymes 
 Hyper-60 for 7 
days, % 
Hyper-85 for 7 
days, % 
Reference 
No. 
NQO1 per g dry wt +64 +40 Present study 
Complex III per g dry wt NS +56 Present study 
Complex I per mg protein −51 −49 Present study 
Complex IV per mg protein NS +90 Present study 
ACE NS −57 Present study 
kox per g dry wt +56 NS Present study 
Lung glutathione content per g 
dry wt 
NS +20 
Present 
Study 
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 Hyper-60 for 7 
days, % 
Hyper-85 for 7 
days, % 
Reference 
No. 
G-6-PDH per g dry wt NS +68 40 
Hexokinase per mg protein NA +44 2 
g-Glutamyltransferase per 
μU/mg 
NS +220 67 
G-6-PDH, glucose-6-phosphate dehydrogenase. NS, not significant; NA, not available. 
Figure 7 shows high correlation between homogenate NQO1 
activity and the capacity (Vmax1) of NQO1-mediated DQ reduction in 
normoxic, hyper-60, and hyper-85 lungs. However, the increase in 
Vmax1 is larger than the increase in NQO1 homogenate activity in 
hyper-60 and hyper-85 lungs. One reason for this difference may be 
that hyperoxia-induced changes in key aspects of the intact lung 
environment that regulate NQO1 activity (e.g., availability of electron 
donors and their accessibility to the enzyme) are not preserved in lung 
homogenates.6 Another reason may be that other dicumarol-
inhibitable reductase(s) besides NQO1 contribute to DQ 
reduction.37,68,72 Although NQO1 is predominantly a cytosolic enzyme 
(>90%),55 noncytosolic NQO1 activity has been previously 
reported.11,37,63 Thus another reason for the above difference may be 
that these O2 levels induced an increase in NQO1 activity in the 
noncytosolic fraction of the lung tissue, which was not preserved in the 
tissue homogenate used for the NQO1 assay. 
 
Fig. 7. Relationship between total NQO1 activity in lung tissue homogenates (Table 2) 
and the capacity (Vmax1) of NQO1 mediated DQ reduction (Table 8) on passage 
through the pulmonary circulation of normoxic, hyper-60, or hyper-85 lungs. Values 
are means ± SE. Solid line is linear model fit (r2 = 0.975). 
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Several studies have evaluated the role of NQO1 in protection 
against pulmonary O2 toxicity.20,70 Whitney and Frank70 found that the 
induction of NQO1 did not significantly improve the survivability of 
adult rats exposed to lethal O2 levels. On the other hand, Cho et al.20 
showed that mice deficient in the transcription factor Nrf2, which is 
involved in the induction of phase II enzymes, including NQO1, had 
significantly lower lung NQO1 mRNA expression and were significantly 
more sensitive to hyperoxia (>95% O2 for 72 h) than wild-type mice. 
Previously, our laboratory demonstrated that rat exposure to hyper-85 
for 21 days, but not for 2 days, increased the capacity of NQO1-
mediated DQ reduction on passage through the lungs and suggested a 
potential role for NQO1 in rat tolerance of 100% O2 toxicity.6,9 One of 
the objectives of this study was to determine whether rat exposure to 
hyper-60 or hyper-85 has a differential effect on the lung activity of 
NQO1. The results of this study reveal that both hyperoxic O2 levels 
increase NQO1 activity in the isolated perfused lung. 
The difference in the rate of DQ efflux during DQH2 infusion in 
the presence of dicumarol (Fig. 3) compared with that in the presence 
of dicumarol plus rotenone (Fig. 5) is consistent with competition 
between infused DQH2 and complex I-generated CoQ9H2 for complex 
III-mediated oxidation. Hence, this difference is a measure of the 
capacity of complex I for generating reducing equivalent (CoQ9H2) and 
of lung tissue rotenone-sensitive O2 consumption. Previously, our 
laboratory estimated the rate of rotenone-sensitive O2 consumption in 
normoxic lungs to be ∼1.4 μmol·min−1·g dry lung wt−1.5 This rate 
(which needs to be multiplied by two for comparison with the 
difference in DQ efflux rate in Fig. 8) is comparable with the maximum 
difference in DQ efflux rate (∼2.4 μmol·min−1·g dry lung wt−1) in 
normoxic lungs (Fig. 8). 
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Fig. 8. The relationship between the difference in steady-state rates (normalized to 
dry lung weight) of DQ efflux and the log mean DQH2 concentrations during DQH2 
arterial infusion in the presence of DIC plus ROT (Fig. 5) and DIC alone (Fig. 3), for 
normoxic lungs, hyper-85 lungs, and hyper-60 lungs. Model-based interpolation was 
used to determine the rates of DQ efflux in the presence of DIC plus ROT (Fig. 5) at 
the same log mean DQH2 concentrations as in Fig. 3. 
For hyper-85 lungs, the difference in the DQ efflux rate in the 
presence of dicumarol or dicumarol plus rotenone (Fig. 8) was 
comparable to that for normoxic lungs. However, for hyper-60 lungs, 
the difference was ∼50% smaller than that for normoxic lungs (Fig. 8). 
This suggests a potential decrease in the capacity of complex I for 
generating CoQ9H2 in hyper-60 lungs compared with normoxic and 
hyper-85 lungs. This could be due to a decrease in lung tissue complex 
I activity and/or decrease in the rate of the metabolic coenzyme NADH 
supplied to complex I. Table 3 shows that exposure to hyper-85 or 
hyper-60 decreased lung complex I activity (per milligram of protein) 
by ∼50%. This decrease appears to have no significant effect on the 
capacity of complex I for generating CoQ9H2 in hyper-85 lungs (Fig. 8), 
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suggesting a possible increase in the rate of NADH supplied to complex 
I to compensate for the decrease in complex I activity. This would be 
consistent with an increase in tissue activities of glucose transporters 
and hexokinase in hyper-85 lungs.3 For hyper-60 lungs, the decrease 
in complex I activity (Table 3) is proportional to the decrease in the 
rate of complex I-generated CoQ9H2 (Fig. 8). 
Ratner et al.53 demonstrated that exposure of neonatal mice to 
hyperoxia (75% O2 for 72 h) decreases complex I activity by ∼70%, 
and that this decrease compromises mitochondrial oxidative 
phosphorylation and contributes to alveolar development arrest. Based 
on these results, they concluded that the decrease in complex I plays 
a key role in lung O2 toxicity. In the present study, exposure to hyper-
60 or hyper-85 decreased complex I activity by ∼50%. However, for 
hyper-85 lungs, the effect of this decrease on oxidative 
phosphorylation may have been countered by an increase in the lung 
activities of glucose transporters and hexokinase upstream from 
complex I,2 and by an increase in the activities of complexes III and IV 
downstream from complex I (Table 9). Additional studies would be 
needed to evaluate the effect of this depression in complex I activity 
on the mitochondrial rate of ATP production. 
Rat exposure to hyper-85, but not hyper-60, increased lung 
tissue activities of complexes III and IV by 56 and 90%, respectively. 
Again, this may be a compensatory mechanism to counter the 
potential effects of the depression in complex I activity on 
mitochondrial ATP production.28 The increase in lung complexes III and 
IV activities could also be a means of decreasing ROS production at 
complexes I and III, since the higher the respiration rate, the less time 
the electrons are delayed at critical leakage sites, such as complexes I 
and III.18,45 Campian et al.18 showed that an O2-tolerant strain of HeLa 
cells had a higher complex IV activity and a lower rate of mitochondrial 
ROS production compared with wild-type HeLa cells. Furthermore, they 
showed that inhibiting the complex IV activity of these O2-tolerant cells 
increased their rate of mitochondrial ROS production and increased 
their sensitivity to hyperoxia. Based on these results, they attributed 
the O2 tolerance of these cells to their higher than normal complex IV 
activity, which results in a tighter coupling of the electron transport 
chain and a lower rate of mitochondrial ROS formation.18 Additional 
studies would be needed to evaluate the effect of the measured 
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increase in tissue complexes III and IV activities of hyper-85 lungs on 
mitochondrial rates of ATP production and ROS formation and to 
determine the role of complexes III and IV in rat tolerance of 100% O2 
toxicity. 
Previous studies have suggested a role for the pentose 
phosphate pathway in rat tolerance of 100% O2.64 This pathway 
provides reducing equivalents (NADPH) for the glutathione redox cycle 
and for the synthesis of cellular components needed for repair 
mechanisms.64 Tierney et al.64 demonstrated an increase in the activity 
of the enzyme G-6-PHD in lungs of rats, but not mice, exposed to 
hyper-85. Hayatdavoudi et al.40 demonstrated an increase in G-6-PHD 
activity in lungs of hyper-85 rats, but not hyper-60 rats. The results of 
the present study demonstrate an increase in lung tissue total 
glutathione (GSH) content per milligram of protein in hyper-85 lungs, 
but not hyper-60 lungs, compared with normoxic lungs (Table 4). This 
result is consistent with an increase in γ-glutamyltransferase activity in 
tissue homogenates of hyper-85 lungs, but not hyper-60 lungs, 
reported by Van Klaveren et al.67 (Table 9). This enzyme is important 
for the uptake of substrates for intracellular GSH synthesis. However, 
in the same study, Van Klaveren et al. reported no increase in GSH 
level in hyper-85 tissue homogenates per milligram protein, which is 
different from the results in the present study.67 This difference may 
be due to differences in rat strains (Wistar vs. Sprague-Dawley) 
and/or the methods used to measure tissue GSH content. The increase 
in GSH content in hyper-85 lung homogenates measured in the 
present study is potentially important, since GSH is the major 
mechanism for scavenging H2O2 in endothelial cells, and since H2O2 is 
the most cytotoxic ROS in endothelial cells, which are a primary target 
of lung O2 toxicity.62 
For hyper-60 lungs, the decrease in complex I activity did not 
stimulate changes in substrate availability, activities of complexes III 
and IV, GSH content, and/or G-6-PDH activity to counter the potential 
effect of a 50% depression in complex I activity on mitochondrial rates 
of ATP production and ROS formation, and on GSH redox cycle. This 
could make hyper-60 lung cells susceptible to further injury by a 
hyperoxia-induced increase in the rate of ROS formation. The increase 
in the susceptibility of hyper-60 rats to 100% O2 toxicity could also be 
due to changes in other cellular processes. For instance, hyper-60 
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rates are more susceptible to mechanical ventilation injury than are 
normoxic rats.40 Additional studies would be needed to evaluate the 
effect of rat exposure to hyper-60 on lung tissue rates of mitochondrial 
ROS formation and ATP production. 
Since mice do not acquire tolerance of 100% O2 following 
exposure to hyper-85,19,26 a lack of increase in complexes III and IV 
activities and GSH content in lungs of mice exposed to hyper-85 would 
provide further evidence for the potential role of these redox processes 
in rat tolerance of 100% O2. However, the inability of mice to acquire 
tolerance of 100% O2 could also be due to changes in other cellular 
processes. 
Rat tolerance of 100% O2 can be induced, not only by 
preexposing rats to hyper-85 for 7 days, but also by other 
experimental means, including rat preexposure to 95% O2 for 48 h, 
followed by a 24-h “rest period” in room air or 50–70% O2 (hyper-
95).33 Thus another approach to providing additional support for the 
potential role of complexes III and IV and GSH redox cycle in rat 
tolerance of 100% O2 would be to demonstrate that their activities also 
increase in lungs of rats exposed to hyper-95. 
Because patients requiring high O2 come with differing 
tolerances of hyperoxia based on genetics, preconditioning, or other 
factors, real-time information that permits clinicians to determine 
which patients are developing toxicity is invaluable.36 The identified 
changes in complexes III and IV and GSH content may provide targets 
for clinical biomarker imaging (e.g., SPECT, PET, MRI) to detect 
tolerance of, or susceptibility to, high O2. For instance, the ability of 
lung tissue to increase its capacity to generate GSH or increase its 
activities of complexes III and IV may be indicative of the ability of a 
critically ill patient to tolerate sustained exposure to O2 at high 
fractions. In contrast, a patient with the same O2 requirement and no 
increase in GSH content or activities of complexes III and IV could be 
at a much higher risk for irreversible lung injury. In this case, the 
patient with evidence of enhanced susceptibility to hyperoxia should be 
a candidate for therapies that otherwise would not be employed 
because of toxicity, e.g., higher positive end-expiratory pressure, 
acceptance of lower arterial O2 tension, extracorporeal membrane 
oxygenation, and moderate hypothermia. 
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In conclusion, the results demonstrate that NQO1 activity 
increased in both hyper-60 and hyper-85 lungs, whereas complex III 
activity increased in hyper-85 lungs only. This increase, along with the 
increase in complex IV activity, substrate availability, and G-6-PHD in 
hyper-85 lungs, could be to counter the effects that the depression in 
complex I activity might have on mitochondrial ATP production and 
ROS formation, and on GSH redox cycle, and hence be important to 
rat tolerance of 100% O2. The results demonstrate the utility of these 
two hyperoxic models and indicator dilution methods for furthering 
understanding of the pathogenesis of lung O2 toxicity and for providing 
insights into the underlying mechanisms of rat tolerance of and 
susceptibility to 100% O2. 
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Glossary 
ACE 
Angiotensin-converting enzyme 
BSA 
Bovine serum albumin 
CoQ9H2 
Endogenous coenzyme Q9 hydroquinone 
DQH2 
Durohydroquinone 
[DQ](x,t) and [DQH2](x,t) 
Vascular concentrations of free DQ and DQH2, respectively, at distance 
x from the capillary inlet and time t (μM) 
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[DQ] 
Total (free + BSA bound) vascular concentration of DQ (μM) 
[DQH2] 
Total (free + BSA bound) vascular concentration of DQH2 (μM) 
hc(t) 
Capillary transit time distribution 
FAPGG 
N-[3-(2-furyl) acryloyl]-Phe-Gly-Gly 
Km1a 
Apparent Michaelis-Menten constant for NQO1-mediated DQ reduction 
(μM) 
Km2a 
Apparent Michaelis-Menten constant for DQH2 oxidation via complex 
III (μM) 
kox 
Tissue-mediated DQH2 oxidation rate on passage through the 
pulmonary circulation in the absence of rotenone (ml/min) 
NQO1 
NAD(P)H:quinone oxidoreductase 1 
PS 
Permeability-surface area product (ml/min), which is a measure of rate 
of ACE-mediated FAPGG hydrolysis, and an index of perfused capillary 
surface area 
Vc 
Volume of the vascular region of the single capillary element model 
(ml) 
Ve 
Volume of the tissue region of the single capillary element model (ml) 
Vmax1 
Maximum rate for DQ reduction via NQO1 (μmol/min) 
Vmax2 
Maximum rate for DQH2 oxidation via complex III (μmol/min) 
VF1/α1 
Virtual volume of distribution for DQ (ml) 
VF2/α2 
Virtual volume of distribution for DQH2 (ml) 
W 
Convective transport velocity (cm/min) 
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Greek Letters 
α1 and α2 
Constants that account for the rapidly equilibrating interactions of DQ 
and DQH2 with the 5% BSA (i.e., Pc) perfusate 
α3 and α4 
Constants that account for the rapidly equilibrating interactions of DQ 
and DQH2 with lung tissue sites of association, respectively 
Appendix 
Based on the single capillary element model depicted in Fig. 6, the species 
balance equations descriptive of spatial and temporal variations in the 
concentrations of DQ, DQH2 in (Vc and Ve) are  
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑡
 + 𝑊 (
V𝑐
 V𝑐 +
VF1
𝛼1
)
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑥
= (
1
V𝑐 +
VF1
𝛼1
) (
𝑉max2[DQH̅̅ ̅̅ ̅̅ 2]
𝐾m2a + [DQH̅̅ ̅̅ ̅̅ 2]
−
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
) 
(A1) 
 
𝜕[DQH̅̅ ̅̅ ̅̅ 2]
𝜕𝑡
+ 𝑊 (
V𝑐
V𝑐 +
VF2
𝛼2
)
𝜕[DQH̅̅ ̅̅ ̅̅ 2]
𝜕𝑥
= (
1
Vc +
VF2
α2
) (
 𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
−
𝑉max2[DQH̅̅ ̅̅ ̅̅ 2]
𝐾m2a + [DQH̅̅ ̅̅ ̅̅ 2]
) 
(A2) 
where W = convective transport velocity = L/t̄ c; x = 0 and x = L are 
the capillary inlet and outlet, respectively; t̄ c is the capillary mean 
transit time; [DQ](x,t), and [DQH2](x,t) are vascular concentrations of 
free DQ and DQH2 forms, respectively, at distance x from the capillary 
inlet and time t; [DQ] = α1 [DQ] and [DQH2] = α2 [DQH2] are the total 
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(free + BSA bound) vascular concentrations of DQ and DQH2, 
respectively; α1 = 1 + (DQ bound fraction/DQ free fraction) = 25 and 
α2 = 1 + (DQH2 bound fraction/DQH2 free fraction) = 4.2 are constants 
that account for the rapidly equilibrating interactions of DQ and DQH2, 
with the 5% BSA (i.e., Pc) perfusate calculated from the fractions of 
DQ and DQH2 bound to BSA obtained by ultrafiltration (5). Vmax1 
(μmol/min) and Vmax2 (μmol/min) are the respective maximum rates 
for DQ reduction via NQO1 and DQH2 oxidation via complex III; Km1a 
(μM) and Km2a (μM) are the apparent Michaelis-Menten constants for 
NQO1 and complex III, respectively. VF1/α1 = (α3/α1) Ve and VF2/α2 = 
(α4/α2) Ve (ml) are the respective virtual volumes of distribution for DQ 
and DQH2, where α3 and α4 are constants that account for the rapidly 
equilibrating interactions of DQ and DQH2 with lung tissue sites (Pe) of 
association, respectively. 
In the absence of rotenone, DQH2 competes with CoQ9H2 for 
oxidation via complex III. This competition explains the observation 
that the rates of DQ efflux during DQH2 infusion in the presence of 
dicumarol alone are lower than those in the presence of dicumarol plus 
rotenone (Figs. 3 and and5).5). Moreover, the steady-state DQ efflux 
rates during DQH2 infusion in the presence of dicumarol alone appear 
to follow linear kinetics for the range of infused DQH2 concentrations 
studied (Fig. 3). Thus, in the absence of rotenone, Vmax2 and Km2a in 
Eqs. A1 and A2 are substituted for with a tissue-mediated DQH2 
oxidation rate kox (ml/min). Equations A1 and A2 become  
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑡
+ 𝑊 (
Vc
Vc +
VF1
α1
)
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑥
= (
1
Vc +
VF1
α1
) (𝑘ox[DQH̅̅ ̅̅ ̅̅ 2] −
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
) 
(A3) 
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𝜕[DQH̅̅ ̅̅ ̅̅ 2]𝜕𝑡 + 𝑊 (
Vc
Vc + VF2α2
)
𝜕[DQH̅̅ ̅̅ ̅̅ 2]
𝜕𝑥
= (
1
Vc +
VF2
α2
) (
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
− 𝑘ox[DQH̅̅ ̅̅ ̅̅ 2]) 
(A4) 
Since our venous effluent data are measured at steady state, we 
considered the steady-state version of Eqs. A1 and A2 and Eqs. A3 and 
A4 obtained by setting all time derivative terms to zero. Thus Eqs. A1 
and A2 and Eqs. A3 and A4 become Eqs. A5 and A6 and Eqs. A7 and 
A8, respectively. Under steady-state conditions, the unknown model 
parameters are Vmax1, Vmax2, Km1a, Km2a, and kox.  
𝑊V𝑐
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑥
= (
𝑉max2[DQH̅̅ ̅̅ ̅̅ 2]
𝐾m2a + [DQH̅̅ ̅̅ ̅̅ 2]
−
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
) 
(A5) 
 
𝑊V𝑐
𝜕[DQH̅̅ ̅̅ ̅̅ 2]
𝜕𝑥
= (
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
−
𝑉max2[DQH̅̅ ̅̅ ̅̅ 2]
𝐾m2a + [DQH̅̅ ̅̅ ̅̅ 2]
) 
(A6) 
 
𝑊V𝑐
𝜕[DQ̅̅ ̅̅ ]
𝜕𝑥
= 𝑘ox[DQH̅̅ ̅̅ ̅̅ 2] −
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
 
(A7) 
 
𝑊V𝑐
𝜕[DQH̅̅ ̅̅ ̅̅ 2]
𝜕𝑥
=
𝑉max1[DQ̅̅ ̅̅ ]
𝐾m1a + [DQ̅̅ ̅̅ ]
− 𝑘ox[DQH̅̅ ̅̅ ̅̅ 2] 
(A8) 
Equations A1 and A2 or Eqs. A3 and A4 are for a single capillary 
element. For the lung model, we accounted for the effect of the hc(t) 
on the plasma concentrations and redox status of DQ and DQH2 on 
passage through the pulmonary circulation (5, 6). Previously, our 
laboratory determined hc(t) for normoxic rat lungs and hyper-85 lungs 
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and demonstrated that rat exposure to hyper-85 for 7 days decreased 
capillary mean transit time by 42% and increased the relative 
dispersion of hc(t) by 40% (52). These values were used in the kinetic 
analysis of the normoxic and hyper-85 lung data. For hyper-60 lungs, 
hc(t) was assumed to be the same as that determined for normoxic 
lungs. This is based on results in Table 1 that show exposure to hyper-
60 for 7 days had no effect on perfused capillary surface area (PS) and 
on previous results that showed rat exposure to hyper-60 for 7 days 
had no significant effect on morphometrically measured lung capillary 
endothelial surface area and capillary volume (40). 
Previously, our laboratory demonstrated that most of the 
dispersion within the lung vascular region is due to the capillary bed 
(52). Thus DQ and DQH2 transit through the arteries and veins was 
represented by a shifted impulse function, where the shift is the 
plasma mean transit time through the arteries and veins, determined 
as previously described (52). 
To model DQ or DQH2 pulse infusions, given hc(t), Eqs. A1 and 
A2 or Eqs. A3 and A4 are solved numerically with appropriate initial (t 
= 0) and boundary (x = 0) conditions (5, 7, 8). To provide the whole 
organ output [DQ] and [DQH2], the outputs for all transit times are 
summed, each weighted according to hc(t), as previously described (5, 
7, 8). 
References 
1 Ahmad S, White CW, Chang LY, Schneider BK, Allen CB. Glutamine protects 
mitochondrial structure and function in oxygen toxicity. Am J Physiol 
Lung Cell Mol Physiol 280: L779–L791, 2001 
2 Allen CB, Guo XL, White CW. Changes in pulmonary expression of 
hexokinase and glucose transporter mRNAs in rats adapted to 
hyperoxia. Am J Physiol Lung Cell Mol Physiol 274: L320–L329, 1998 
3 Allen CB, White CW. Glucose modulates cell death due to normobaric 
hyperoxia by maintaining cellular ATP. Am J Physiol Lung Cell Mol 
Physiol 274: L159–L164, 1998 
4 Altemeier WA, Sinclair SE. Hyperoxia in the intensive care unit: why more is 
not always better. Curr Opin Crit Care 13: 73–78, 2007 
5 Audi SH, Bongard RD, Dawson CA, Siegel D, Roerig DL, Merker MP. 
Duroquinone reduction during passage through the pulmonary 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
35 
 
circulation. Am J Physiol Lung Cell Mol Physiol 285: L1116–L1131, 
2003 
6 Audi SH, Bongard RD, Krenz GS, Rickaby DA, Haworth ST, Eisenhauer J, 
Roerig DL, Merker MP. Effect of chronic hyperoxic exposure on 
duroquinone reduction in adult rat lungs. Am J Physiol Lung Cell Mol 
Physiol 289: L788–L797, 2005 
7 Audi SH, Dawson CA, Ahlf SB, Roerig DL. Oxygen dependency of 
monoamine oxidase activity in the intact lung. Am J Physiol Lung Cell 
Mol Physiol 281: L969–L981, 2001 
8 Audi SH, Linehan JH, Krenz GS, Dawson CA. Accounting for the 
heterogeneity of capillary transit times in modeling multiple indicator 
dilution data. Ann Biomed Eng 26: 914–930, 1998 
9 Audi SH, Merker MP, Krenz GS, Ahuja T, Roerig DL, Bongard RD. Coenzyme 
Q1 redox metabolism during passage through the rat pulmonary 
circulation and the effect of hyperoxia. J Appl Physiol 105: 1114–1126, 
2008 
10 Bassingthwaighte JB, Goresky CA, Linehan JH. Whole Organ Approaches to 
Cellular Metabolism: Permeation, Cellular Uptake, and Product 
Formation. New York: Springer, 1998 
11 Beattie DS, Japa S, Howton M, Zhu QS. Direct interaction between the 
internal NADH:ubiquinone oxidoreductase and ubiquinol:cytochrome c 
oxidoreductase in the reduction of exogenous quinones by yeast 
mitochondria. Arch Biochem Biophys 292: 499–505, 1992 
12 Beyer RE, Segura-Aguilar J, Di Bernardo S, Cavazzoni M, Fato R, Fiorentini 
D, Galli MC, Setti M, Landi L, Lenaz G. The role of DT-diaphorase in the 
maintenance of the reduced antioxidant form of coenzyme Q in 
membrane systems. Proc Natl Acad Sci U S A 93: 2528–2532, 1996 
13 Bongard RD, Lindemer BJ, Krenz GS, Merker MP. Preferential utilization of 
NADPH as the endogenous electron donor for NAD(P)H:quinone 
oxidoreductase 1 (NQO1) in intact pulmonary arterial endothelial cells. 
Free Radic Biol Med 46: 25–32, 2009 
14 Boveris A, Oshino R, Erecinska M, Chance B. Reduction of mitochondrial 
components by durohydroquinone. Biochim Biophys Acta 245: 1–16, 
1971 
15 Brueckl C, Kaestle S, Kerem A, Habazettl H, Krombach F, Kuppe H, Kuebler 
WM. Hyperoxia-induced reactive oxygen species formation in 
pulmonary capillary endothelial cells in situ. Am J Respir Cell Mol Biol 
34: 453–463, 2006 
16 Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in 
quinone metabolism. Biochem Pharmacol 49: 127–140, 1995 
17 Cadenas E, Boveris A, Ragan CI, Stoppani AO. Production of superoxide 
radicals and hydrogen peroxide by NADH-ubiquinone reductase and 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
36 
 
ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch 
Biochem Biophys 180: 248–257, 1977 
18 Campian JL, Qian M, Gao X, Eaton JW. Oxygen tolerance and coupling of 
mitochondrial electron transport. J Biol Chem 279: 46580–46587, 
2004 
19 Capellier G, Maupoil V, Boussat S, Laurent E, Neidhardt A. Oxygen toxicity 
and tolerance. Minerva Anestesiol 65: 388–392, 1999 
20 Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, 
Kleeberger SR. Role of NRF2 in protection against hyperoxic lung 
injury in mice. Am J Respir Cell Mol Biol 26: 175–182, 2002 
21 Chow CW, Herrera Abreu MT, Suzuki T, Downey GP. Oxidative stress and 
acute lung injury. Am J Respir Cell Mol Biol 29: 427–431, 2003 
22 Clark JM, Lambertsen CJ. Pulmonary oxygen toxicity: a review. Pharmacol 
Rev 23: 37–133, 1971 
23 Coursin DB, Cihla HP, Will JA, McCreary JL. Adaptation to chronic 
hyperoxia. Biochemical effects and the response to subsequent lethal 
hyperoxia. Am Rev Respir Dis 135: 1002–1006, 1987 
24 Crapo JD, Barry BE, Foscue HA, Shelburne J. Structural and biochemical 
changes in rat lungs occurring during exposures to lethal and adaptive 
doses of oxygen. Am Rev Respir Dis 122: 123–143, 1980 
25 Crapo JD, Peters-Golden M, Marsh-Salin J, Shelburne JS. Pathologic 
changes in the lungs of oxygen-adapted rats: a morphometric 
analysis. Lab Invest 39: 640–653, 1978 
26 Crapo JD, Tierney DF. Superoxide dismutase and pulmonary oxygen 
toxicity. Am J Physiol 226: 1401–1407, 1974 
27 Davis WB, Rennard SI, Bitterman PB, Crystal RG. Pulmonary oxygen 
toxicity. Early reversible changes in human alveolar structures induced 
by hyperoxia. N Engl J Med 309: 878–883, 1983 
28 Desquiret V, Gueguen N, Malthiery Y, Ritz P, Simard G. Mitochondrial 
effects of dexamethasone imply both membrane and cytosolic-initiated 
pathways in HepG2 cells. Int J Biochem Cell Biol 40: 1629–1641, 2008 
29 Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinone reductase 
type 1 (DT diaphorase) protects cells against the toxicity of 
electrophiles and reactive forms of oxygen. Free Radic Biol Med 29: 
231–240, 2000 
30 Fisher AB, Beers MF. Hyperoxia and acute lung injury. Am J Physiol Lung 
Cell Mol Physiol 295: L1066–L1067, 2008  
31 Fisher AB, Forman HJ, Glass M. Mechanisms of pulmonary oxygen toxicity. 
Lung 162: 255–259, 1984 
32 Frank L, Bucher JR, Roberts RJ. Oxygen toxicity in neonatal and adult 
animals of various species. J Appl Physiol 45: 699–704, 1978 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
37 
 
33 Frank L, Iqbal J, Hass M, Massaro D. New “rest period” protocol for inducing 
tolerance to high O2 exposure in adult rats. Am J Physiol Lung Cell Mol 
Physiol 257: L226–L231, 1989 
34 Freeman BA, Crapo JD. Hyperoxia increases oxygen radical production in 
rat lungs and lung mitochondria. J Biol Chem 256: 10986–10992, 
1981 
36 Gao L, Barnes KC. Recent advances in genetic predisposition to clinical 
acute lung injury. Am J Physiol Lung Cell Mol Physiol 296: L713–L725, 
2009 
37 Gonzalez-Aragon D, Ariza J, Villalba JM. Dicoumarol impairs mitochondrial 
electron transport and pyrimidine biosynthesis in human myeloid 
leukemia HL-60 cells. Biochem Pharmacol 73: 427–439, 2007 
38 Griffith DE, Holden WE, Morris JF, Min LK, Krishnamurthy GT. Effects of 
common therapeutic concentrations of oxygen on lung clearance of 
99mTc DTPA and bronchoalveolar lavage albumin concentration. Am 
Rev Respir Dis 134: 233–237, 1986 
39 Griffith OW. Determination of glutathione and glutathione disulfide using 
glutathione reductase and 2-vinylpyridine. Anal Biochem 106: 207–
212, 1980 
40 Hayatdavoudi G, O'Neil JJ, Barry BE, Freeman BA, Crapo JD. Pulmonary 
injury in rats following continuous exposure to 60% O2 for 7 days. J 
Appl Physiol 51: 1220–1231, 1981 
41 Ho YS. Transgenic and knockout models for studying the role of lung 
antioxidant enzymes in defense against hyperoxia. Am J Respir Crit 
Care Med 166: S51–S56, 2002 
42 Ho YS, Dey MS, Crapo JD. Antioxidant enzyme expression in rat lungs 
during hyperoxia. Am J Physiol Lung Cell Mol Physiol 270: L810–L818, 
1996 
43 Kimball RE, Reddy K, Peirce TH, Schwartz LW, Mustafa MG, Cross CE. 
Oxygen toxicity: augmentation of antioxidant defense mechanisms in 
rat lung. Am J Physiol 230: 1425–1431, 1976 
44 Lenaz G, Fato R, Baracca A, Genova ML. Mitochondrial quinone reductases: 
complex I. Methods Enzymol 382: 3–20, 2004 
45 Li J, Gao X, Qian M, Eaton JW. Mitochondrial metabolism underlies 
hyperoxic cell damage. Free Radic Biol Med 36: 1460–1470, 2004 
46 Mantell LL, Horowitz S, Davis JM, Kazzaz JA. Hyperoxia-induced cell death 
in the lung–the correlation of apoptosis, necrosis, and inflammation. 
Ann N Y Acad Sci 887: 171–180, 1999 
47 O'Brodovich HM, Mellins RB. Bronchopulmonary dysplasia. Unresolved 
neonatal acute lung injury. Am Rev Respir Dis 132: 694–709, 1985 
48 Otterbein LE, Choi AM. The saga of leucine zippers continues: in response 
to oxidative stress. Am J Respir Cell Mol Biol 26: 161–163, 2002 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
38 
 
49 Owens CW, Belcher RV. A colorimetric micro-method for the determination 
of glutathione. Biochem J 94: 705–711, 1965 
50 Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales 
DC, Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, 
Stewart TE, Ferguson ND. Has mortality from acute respiratory 
distress syndrome decreased over time?: A systematic review. Am J 
Respir Crit Care Med 179: 220–227, 2009 
51 Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, 
Jaiswal AK. Disruption of the DT diaphorase (NQO1) gene in mice leads 
to increased menadione toxicity. J Biol Chem 273: 7382–7389, 1998 
52 Ramakrishna M, Gan Z, Clough AV, Molthen RC, Roerig DL, Audi SH. 
Distribution of capillary transit times in isolated lungs of oxygen-
tolerant rats. Ann Biomed Eng 38: 3449–3465, 2010  
53 Ratner V, Starkov A, Matsiukevich D, Polin RA, Ten VS. Mitochondrial 
dysfunction contributes to alveolar developmental arrest in hyperoxia-
exposed mice. Am J Respir Cell Mol Biol 40: 511–518, 2009 
54 Rogers LK, Tipple TE, Nelin LD, Welty SE. Differential responses in the 
lungs of newborn mouse pups exposed to 85% or >95% oxygen. 
Pediatr Res 65: 33–38, 2009 
55 Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone 
oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene 
regulation and genetic polymorphisms. Chem Biol Interact 129: 77–
97, 2000 
56 Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW. DT-
diaphorase in activation and detoxification of quinones. Bioreductive 
activation of mitomycin C. Cancer Metastasis Rev 12: 83–101, 1993 
57 Saugstad OD. Optimal oxygenation at birth and in the neonatal period. 
Neonatology 91: 319–322, 2007 
58 Schoonen WG, Wanamarta AH, van der Klei-van Moorsel JM, Jakobs C, 
Joenje H. Respiratory failure and stimulation of glycolysis in Chinese 
hamster ovary cells exposed to normobaric hyperoxia. J Biol Chem 
265: 1118–1124, 1990 
59 Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross 
D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide 
scavenger. Mol Pharmacol 65: 1238–1247, 2004 
60 Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 
(NQO1) in human tissues. Free Radic Biol Med 29: 246–253, 2000 
61 Storrie B, Madden EA. Isolation of subcellular organelles. Methods Enzymol 
182: 203–225, 1990 
62 Suttorp N, Toepfer W, Roka L. Antioxidant defense mechanisms of 
endothelial cells: glutathione redox cycle versus catalase. Am J Physiol 
Cell Physiol 251: C671–C680, 1986 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Applied Physiology, Vol 111, No. 1 (July 2011): pg. 95-107. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
39 
 
63 Tan AS, Berridge MV. Evidence for NAD(P)H:quinone oxidoreductase 1 
(NQO1)-mediated quinone-dependent redox cycling via plasma 
membrane electron transport: a sensitive cellular assay for NQO1. 
Free Radic Biol Med 48: 421–429, 2010 
64 Tierney D, Ayers L, Herzog S, Yang J. Pentose pathway and production of 
reduced nicotinamide adenine dinucleotide phosphate. A mechanism 
that may protect lungs from oxidants. Am Rev Respir Dis 108: 1348–
1351, 1973 
65 Tietze F. Enzymic method for quantitative determination of nanogram 
amounts of total and oxidized glutathione: applications to mammalian 
blood and other tissues. Anal Biochem 27: 502–522, 1969 
66 Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 
552: 335–344, 2003 
67 Van Klaveren RJ, Dinsdale D, Pype JL, Demedts M, Nemery B. Changes in 
gamma-glutamyltransferase activity in rat lung tissue, BAL, and type 
II cells after hyperoxia. Am J Physiol Lung Cell Mol Physiol 273: L537–
L547, 1997 
68 Von Jagow G, Bohrer C. Inhibition of electron transfer from 
ferrocytochrome b to ubiquinone, cytochrome c1 and duroquinone by 
antimycin. Biochim Biophys Acta 387: 409–424, 1975 
69 Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB. Lung injury and 
mortality with hyperoxia are increased in peroxiredoxin 6 gene-
targeted mice. Free Radic Biol Med 37: 1736–1743, 2004 
70 Whitney PL, Frank L. Does lung NAD(P)H:quinone reductase (DT-
diaphorase) play an antioxidant enzyme role in protection from 
hyperoxia? Biochim Biophys Acta 1156: 275–282, 1993 
71 Zhu H, Jia Z, Mahaney JE, Ross D, Misra HP, Trush MA, Li Y. The highly 
expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 
1 in cardiovascular cells acts as a potential superoxide scavenger. 
Cardiovasc Toxicol 7: 202–211, 2007 
72 Zhu QS, Beattie DS. Direct interaction between yeast NADH-ubiquinone 
oxidoreductase, succinate-ubiquinone oxidoreductase, and ubiquinol-
cytochrome c oxidoreductase in the reduction of exogenous quinones. 
J Biol Chem 263: 193–199, 1988 
 
 
Corresponding author. 
Address for reprint requests and other correspondence: S. H. Audi, Research 
Service 151, Zablocki VAMC, 5000 W. National Ave., Milwaukee, WI 53295 (e-
mail: said.audi@mu.edu 
 
 
